21/04/2022

III Congress of Orthobiology 2022 "From research to clinical practice"

On April 15-16, 2022, Fidia Russia took part in the III Congress of Orthobiology 2022 "From research to clinical practice"
The event was held in face-to-face format. For 2 days, the event was attended by 400 specialists.
Within the framework of the session "Regenerative technologies in arthroscopic, minimally invasive and organ-preserving surgery" events a report was presented “Evidence base for the use of hyaluronates: from the patient to the choice of the drug”.
In the report was highlighted the importance of personified HA product selection for patients with OA with strong evidence in clinical trials. To date, the products of the Fidia Pharma have the largest evidence base, which helps specialists make the right choice.

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Other product websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.